for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Daito Pharmaceutical Co.,Ltd.

4577.T

Latest Trade

3,240.00JPY

Change

15.00(+0.47%)

Volume

18,300

Today's Range

3,190.00

 - 

3,245.00

52 Week Range

2,688.00

 - 

3,750.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,225.00
Open
3,225.00
Volume
18,300
3M AVG Volume
0.55
Today's High
3,245.00
Today's Low
3,190.00
52 Week High
3,750.00
52 Week Low
2,688.00
Shares Out (MIL)
12.52
Market Cap (MIL)
40,567.86
Forward P/E
11.48
Dividend (Yield %)
1.18

Next Event

Dividend For 4577.T - 20.0000 JPY

Latest Developments

More

Medical System Network unit says business alliance with Daito Pharmaceutical

Daito Pharmaceutical to build new building for pharmaceutical production

Daito Pharmaceutical says Yoshihiro Narai to resign as chairman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Daito Pharmaceutical Co.,Ltd.

Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Industry

Biotechnology & Drugs

Contact Info

326, Yoka-machi

+81.76.4215665

http://www.daitonet.co.jp

Executive Leadership

Yasunobu Ohtsuga

President, Representative Director

Junichi Kikuta

Senior Managing Director

Mitsuo Hirono

Managing Executive Officer, Chief Director of Purchasing & Logistics

Masuo Nomura

Managing Executive Officer, Chief Director of Administration, Manager of Business Planning Office

Masamichi Takimoto

Managing Executive Officer, Chief Director of Pharmaceuticals

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

212.260

2018

243.080

2019

280.730

2020(E)

279.700
Price To Earnings (TTM)
10.99
Price To Sales (TTM)
0.94
Price To Book (MRQ)
1.27
Price To Cash Flow (TTM)
6.20
Total Debt To Equity (MRQ)
14.16
LT Debt To Equity (MRQ)
8.48
Return on Investment (TTM)
10.70
Return on Equity (TTM)
7.58

Latest News

Latest News

BRIEF-Medical System Network unit says business alliance with Daito Pharmaceutical

* Says Sapporo-based pharmaceutical unit forms business alliance with Daito Pharmaceutical Co Ltd on Feb. 16, and mainly cooperate on provision of joint developed drug

BRIEF-Daito Pharmaceutical to build new building for pharmaceutical production

* Says it will build a new building for pharmaceutical production in October and invest 3.5 billion yen

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up